Klaus D J, Gallione C J, Anthony K, Yeh E Y, Yu J, Lux A, Johnson D W, Marchuk D A
Department of Genetics, Duke University Medical Center, USA.
Hum Mutat. 1998;12(2):137. doi: 10.1002/(SICI)1098-1004(1998)12:2<137::AID-HUMU16>3.0.CO;2-J.
Hereditary hemmorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by multisystemic vascular dyplasia and recurrent hemorrhage. One of the causative genes is the activin receptor-like kinase-1 (ALK-1) gene located on chromosome 12q13. ALK-1 is an endothelial cell type I receptor for the TGF-beta superfamily of ligands. As a number of mutations have been identified in the kinase domain of ALK-1, we initiated a mutation analysis specifically targeting the first four coding exons of ALK-1 in order to determine if mutations in the extracellular and transmembrane domains are also present in HHT. Six new mutations have been identified. Three frameshift mutations were identified in exons encoding the extracellular and transmembrane domains. These mutations would grossly truncate the ALK-1 protein and are thus classic null alleles. Three new missense mutations within the exons encoding the extracellular domain, in addition to two previously described missense mutations, are located at or near highly conserved cysteines. These mutations may disrupt intra- or inter-molecular disulfide bridges required for ligand binding. The combined data suggest that both severe and subtle changes in the ALK-1 amino acid sequence can lead to receptor dysfunction and result in the HHT disease phenotype.
遗传性出血性毛细血管扩张症(HHT)是一种常染色体显性疾病,其特征为多系统血管发育异常和反复出血。致病基因之一是位于12q13染色体上的激活素受体样激酶-1(ALK-1)基因。ALK-1是转化生长因子-β超家族配体的内皮细胞I型受体。由于在ALK-1的激酶结构域中已鉴定出许多突变,我们启动了一项针对ALK-1前四个编码外显子的突变分析,以确定细胞外和跨膜结构域中的突变是否也存在于HHT中。已鉴定出六个新突变。在编码细胞外和跨膜结构域的外显子中鉴定出三个移码突变。这些突变将严重截短ALK-1蛋白,因此是典型的无效等位基因。除了两个先前描述的错义突变外,在编码细胞外结构域的外显子中有三个新的错义突变位于高度保守的半胱氨酸处或其附近。这些突变可能会破坏配体结合所需的分子内或分子间二硫键。综合数据表明,ALK-1氨基酸序列的严重和细微变化均可导致受体功能障碍并导致HHT疾病表型。